Studies from our lab and others in T47D and MCF-7 breast cancer cells have shown that PI3K/AKT and RAF/MEK/ERK pathways are activated in parallel following PRL treatment, which leads to profound cell proliferation and survival [30,31]. The gene discussed is MAP2K7; the disease is breast cancer.